Abstract:Both sorafenib (SOR) and regorafenib (REG), which are structurally similar, can form drug–drug cocrystals with 5-fluorouracil (FU). However, while SOR-FU could be prepared easily by the slurry approach, the elusive REG-FU could not be prepared without the seeds of SOR-FU. The influence of the fluoro substitution of SOR on the cocrystal formation is understood by considering the phase solubility diagrams (PSD) in methanol and acetonitrile and changes in free energy and lattice energy upon cocrystallization using experimental and computational approaches. On the basis of the value of the free energy change upon cocrystal formation, the cocrystallization of REG-FU is less thermodynamically favored than that of SOR-FU. Additionally, the REG-FU formation also faces a higher kinetic barrier due to conformational differences, which lead to the failure of spontaneous cocrystallization from REG and FU. Thus, a subtle molecular structure modification of one coformer significantly influenced the ease of cocrystallization. The heteroseeding strategy was used to overcome both thermodynamic and kinetic barriers for REG-FU synthesis. This strategy may be useful to prepare new pharmaceutical cocrystals of structurally similar compounds in the drug discovery pipeline.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.cgd.1c00512.Structure overlays of SOR-FU and REG-FU before and after the optimization, 1H NMR of REG free base, FU, and REG-FU cocrystal in DMSO, energy framework of SOR-FU, moisture sorption isotherms of SOR-FU and REG-FU cocrystals, stability of SOR-FU and REG-FU powders under accelerated conditions for 2 months, stabilities of SOR-FU and REG-FU in PBS (pH 6.5, 0.1% Tween 80) and methanol, COSY spectra of the SOR+FU combination and the REG+FU combination, phase solubility diagrams of SOR-FU and REG-FU in methanol, intermolecular interaction energies, and hydrogen-bonding distances and angles (PDF)This article has not yet been cited by other publications.

Cocrystals of regorafenib with dicarboxylic acids: synthesis, characterization and property evaluation

Cocrystallization of axitinib with carboxylic acids: preparation, crystal structures and dissolution behavior

Preparation, characterization and antitumor effects of cyclodextrin inclusion complexes of regorafenib

[Preparation, Characterization and Antitumor of Cyclodextrin Inclusion of an Anti-Cancer Drug Regorafenib].

A novel drug-drug cocrystal of tegafur and myricetin: optimized properties of dissolution and tabletability

Evaluation of Molecular Chaperone Drug Function: Regorafenib and Β-Cyclodextrins

An Elusive Drug–Drug Cocrystal Prepared Using a Heteroseeding Strategy

Isomorphous Crystals Formed by the Similar Supramolecular Motifs in Sorafenib Hydrochloride and Regorafenib Hydrochloride Salts

The bioavailability enhancement and insight into the action mechanism of poorly soluble natural compounds from co-crystals preparation: oridonin as an example

“Drug–Coformer–Drug” Multicomponent Crystals to Simultaneously Improve the Solubility of Two Insoluble Combined Drugs by Introduction of a Soluble Coformer

A Drug–Drug Cocrystal of Dihydromyricetin and Pentoxifylline

Strategy to Tune the Performance of Two Drug Components: Drug–Drug Cocrystals of Lobaplatin with Flavonoids

Improving physicochemical properties of Ibrutinib with cocrystal strategy based on structures and natures of the carboxylic acid co-formers

Novel Pharmaceutical Cocrystals of Tegafur: Synthesis, Performance, and Theoretical Studies

New Cocrystals of Antipsychotic Drug Aripiprazole: Decreasing the Dissolution through Cocrystallization

A Drug–Drug Cocrystal Strategy to Regulate Stability and Solubility: A Case Study of Temozolomide/Caffeic Acid

Pharmaceutical Cocrystals: A Novel Systematic Approach for the Administration of Existing Drugs in New Crystalline Form

Study on Typical Diarylurea Drugs or Derivatives in Cocrystallizing with Strong H-Bond Acceptor DMSO

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate

Drug-Drug Cocrystal Alloy and Nanoformulation of Cytarabine: Optimized Biopharmaceutical Property and Synergistic Antitumor Efficacy

Cocrystal of Apixaban–Quercetin: Improving Solubility and Bioavailability of Drug Combination of Two Poorly Soluble Drugs